Lymphoma Drug Acalabrutinib A Potential Therapy For Severe COVID-19?

Sailender26 Aug, 2020Health

A group of researchers made the recent observation that the lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection. The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation. This exploratory study was published on June 5 in Science Immunology.